vs
UNIVERSAL TECHNICAL INSTITUTE INC（UTI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
UNIVERSAL TECHNICAL INSTITUTE INC的季度营收约是再鼎医药的1.7倍（$220.8M vs $127.1M），再鼎医药同比增速更快（17.1% vs 9.6%），UNIVERSAL TECHNICAL INSTITUTE INC自由现金流更多（$-19.2M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 9.5%）
环球技术学院（UTI）是美国的营利性私立技术院校集团，1965年由罗伯特·斯威特创立，专注于提供职业技术类教育课程，培养符合产业需求的技能型人才，在美职业教育领域拥有较长的运营历史与行业经验。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
UTI vs ZLAB — 直观对比
营收规模更大
UTI
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出7.5%
9.6%
自由现金流更多
UTI
多$7.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
9.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $220.8M | $127.1M |
| 净利润 | $12.8M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 7.1% | -54.6% |
| 净利率 | 5.8% | — |
| 营收同比 | 9.6% | 17.1% |
| 净利润同比 | -42.1% | — |
| 每股收益（稀释后） | $0.23 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收UTIZLAB
| Q4 25 | $220.8M | $127.1M | ||
| Q3 25 | $222.4M | $115.4M | ||
| Q2 25 | $204.3M | $109.1M | ||
| Q1 25 | $207.4M | $105.7M | ||
| Q4 24 | $201.4M | $108.5M | ||
| Q3 24 | $196.4M | $101.8M | ||
| Q2 24 | $177.5M | $100.1M | ||
| Q1 24 | $184.2M | $87.1M |
净利润UTIZLAB
| Q4 25 | $12.8M | — | ||
| Q3 25 | $18.8M | $-36.0M | ||
| Q2 25 | $10.7M | $-40.7M | ||
| Q1 25 | $11.4M | $-48.4M | ||
| Q4 24 | $22.2M | — | ||
| Q3 24 | $18.8M | $-41.7M | ||
| Q2 24 | $5.0M | $-80.3M | ||
| Q1 24 | $7.8M | $-53.5M |
毛利率UTIZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率UTIZLAB
| Q4 25 | 7.1% | -54.6% | ||
| Q3 25 | 11.2% | -42.3% | ||
| Q2 25 | 6.9% | -50.3% | ||
| Q1 25 | 8.1% | -53.3% | ||
| Q4 24 | 13.6% | -62.6% | ||
| Q3 24 | 13.3% | -66.6% | ||
| Q2 24 | 4.2% | -76.0% | ||
| Q1 24 | 6.1% | -80.7% |
净利率UTIZLAB
| Q4 25 | 5.8% | — | ||
| Q3 25 | 8.4% | -31.2% | ||
| Q2 25 | 5.2% | -37.3% | ||
| Q1 25 | 5.5% | -45.8% | ||
| Q4 24 | 11.0% | — | ||
| Q3 24 | 9.6% | -40.9% | ||
| Q2 24 | 2.8% | -80.2% | ||
| Q1 24 | 4.2% | -61.4% |
每股收益（稀释后）UTIZLAB
| Q4 25 | $0.23 | $-0.05 | ||
| Q3 25 | $0.33 | $-0.03 | ||
| Q2 25 | $0.19 | $-0.04 | ||
| Q1 25 | $0.21 | $-0.04 | ||
| Q4 24 | $0.40 | $-0.09 | ||
| Q3 24 | $0.35 | $-0.04 | ||
| Q2 24 | $0.09 | $-0.08 | ||
| Q1 24 | $0.14 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $162.8M | $689.6M |
| 总债务越低越好 | $101.4M | — |
| 股东权益账面价值 | $335.9M | $715.5M |
| 总资产 | $834.0M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资UTIZLAB
| Q4 25 | $162.8M | $689.6M | ||
| Q3 25 | $169.1M | $717.2M | ||
| Q2 25 | $70.7M | $732.2M | ||
| Q1 25 | $96.0M | $757.3M | ||
| Q4 24 | $172.0M | $779.7M | ||
| Q3 24 | $161.9M | $616.1M | ||
| Q2 24 | $115.5M | $630.0M | ||
| Q1 24 | $116.1M | $650.8M |
总债务UTIZLAB
| Q4 25 | $101.4M | — | ||
| Q3 25 | $87.1M | — | ||
| Q2 25 | $73.8M | — | ||
| Q1 25 | $94.4M | — | ||
| Q4 24 | $120.1M | — | ||
| Q3 24 | $125.7M | — | ||
| Q2 24 | $137.3M | — | ||
| Q1 24 | $141.9M | — |
股东权益UTIZLAB
| Q4 25 | $335.9M | $715.5M | ||
| Q3 25 | $328.1M | $759.9M | ||
| Q2 25 | $306.8M | $791.7M | ||
| Q1 25 | $293.9M | $810.8M | ||
| Q4 24 | $280.0M | $840.9M | ||
| Q3 24 | $260.2M | $667.7M | ||
| Q2 24 | $239.4M | $704.2M | ||
| Q1 24 | $232.6M | $762.2M |
总资产UTIZLAB
| Q4 25 | $834.0M | $1.2B | ||
| Q3 25 | $826.1M | $1.2B | ||
| Q2 25 | $740.8M | $1.2B | ||
| Q1 25 | $720.4M | $1.2B | ||
| Q4 24 | $753.8M | $1.2B | ||
| Q3 24 | $744.6M | $985.3M | ||
| Q2 24 | $706.0M | $987.4M | ||
| Q1 24 | $702.1M | $988.4M |
负债/权益比UTIZLAB
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.27× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.61× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-19.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | -8.7% | -21.0% |
| 资本支出强度资本支出/营收 | 10.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.24× | — |
| 过去12个月自由现金流最近4个季度 | $16.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流UTIZLAB
| Q4 25 | $3.1M | $-26.0M | ||
| Q3 25 | $57.1M | $-32.0M | ||
| Q2 25 | $18.1M | $-31.0M | ||
| Q1 25 | $-789.0K | $-61.7M | ||
| Q4 24 | $23.0M | $-55.8M | ||
| Q3 24 | $67.5M | $-26.8M | ||
| Q2 24 | $10.0M | $-42.2M | ||
| Q1 24 | $-2.5M | $-90.1M |
自由现金流UTIZLAB
| Q4 25 | $-19.2M | $-26.7M | ||
| Q3 25 | $40.6M | $-35.0M | ||
| Q2 25 | $6.8M | $-33.9M | ||
| Q1 25 | $-11.7M | $-63.2M | ||
| Q4 24 | $19.6M | $-58.4M | ||
| Q3 24 | $60.0M | $-28.2M | ||
| Q2 24 | $3.0M | $-42.9M | ||
| Q1 24 | $-8.4M | $-91.1M |
自由现金流率UTIZLAB
| Q4 25 | -8.7% | -21.0% | ||
| Q3 25 | 18.3% | -30.4% | ||
| Q2 25 | 3.4% | -31.1% | ||
| Q1 25 | -5.7% | -59.9% | ||
| Q4 24 | 9.7% | -53.8% | ||
| Q3 24 | 30.6% | -27.7% | ||
| Q2 24 | 1.7% | -42.9% | ||
| Q1 24 | -4.6% | -104.5% |
资本支出强度UTIZLAB
| Q4 25 | 10.1% | 0.5% | ||
| Q3 25 | 7.4% | 2.6% | ||
| Q2 25 | 5.5% | 2.6% | ||
| Q1 25 | 5.3% | 1.5% | ||
| Q4 24 | 1.7% | 2.4% | ||
| Q3 24 | 3.8% | 1.3% | ||
| Q2 24 | 4.0% | 0.7% | ||
| Q1 24 | 3.2% | 1.1% |
现金转化率UTIZLAB
| Q4 25 | 0.24× | — | ||
| Q3 25 | 3.04× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | -0.07× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 3.58× | — | ||
| Q2 24 | 2.01× | — | ||
| Q1 24 | -0.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
